Managing hemodynamic stability during surgery represents one of the most critical challenges in geriatric anesthesia. Intraoperative hypotension frequently threatens microvascular organ perfusion, particularly within the aging brain. Consequently, anesthesiologists must aggressively preserve cerebral blood flow to mitigate acute neurological decline. Postoperative delirium in elderly patients remains an alarming complication that increases intensive care admissions, hospital lengths of stay, and long-term cognitive deterioration. Although clinicians routinely use vasopressor infusions to restore systemic vascular resistance, uncertainty persists regarding the optimal pharmacological agent. Therefore, evaluating how specific vasopressors affect brain oxygenation has become a major research priority in perioperative medicine.

The Pathophysiology of Intraoperative Hypotension and Cerebral Perfusion

The aging brain possesses limited physiological reserve and altered vascular autoregulation. When arterial pressure drops significantly below baseline during general anesthesia, cerebral perfusion pressure diminishes rapidly. Consequently, transient hypoperfusion triggers neuronal metabolic stress and microglial neuroinflammation. These cellular insults directly accelerate the development of acute confusion and encephalopathy following emergence from anesthesia. Furthermore, pre-existing cerebrovascular disease and arterial stiffness exacerbate this vulnerability in older surgical candidates.

Standard clinical practice often defines intraoperative hypotension as a drop in mean arterial pressure exceeding twenty percent of pre-induction values. However, systemic arterial pressure does not always reflect microvascular cerebral capillary flow. Vasopressors correct systemic numbers through divergent physiological pathways. While some medications restore pressure by constricting downstream vascular beds, others simultaneously support forward stroke volume. Therefore, maintaining cerebral oxygen saturation requires an optimal balance between mean arterial pressure and cardiac output. If a chosen drug restores systemic blood pressure solely through intense vasoconstriction, it may compromise intracranial capillary exchange. Understanding this delicate physiological balance is essential for preventing perioperative cerebral ischemia.

Phenylephrine Versus Ephedrine: Hemodynamic Mechanisms

Phenylephrine and ephedrine operate through distinct adrenergic mechanisms, resulting in contrasting cardiovascular and cerebrovascular profiles. Phenylephrine acts as a selective alpha-1 adrenergic agonist. It produces rapid, potent peripheral vasoconstriction, effectively raising systemic vascular resistance and restoring mean arterial pressure. However, this pure vasoconstriction often triggers baroreceptor-mediated reflex bradycardia. Consequently, phenylephrine frequently decreases stroke volume and total cardiac output. Multiple physiological investigations demonstrate that this drop in cardiac output can lower regional cerebral oxygen saturation, despite seemingly adequate arterial pressure readings.

In contrast, ephedrine functions as a mixed alpha- and beta-adrenergic agonist while stimulating endogenous norepinephrine release. Its beta-1 activity increases myocardial contractility and heart rate, thereby preserving or enhancing forward cardiac output. Concurrently, its alpha-1 agonism provides sufficient vascular tone to elevate systemic perfusion pressure. Because cerebral blood flow depends heavily on forward cardiac output rather than blood pressure alone, ephedrine may sustain cerebral tissue oxygenation more effectively during anesthesia. Nevertheless, ephedrine carries distinct clinical challenges, including tachyphylaxis during continuous infusion and potential risk of excessive tachyarrhythmias. Therefore, clinicians require robust comparative trial data to establish which pharmacological approach truly optimizes perioperative neurological safety.

Preventing Postoperative Delirium in Elderly Surgical Patients

Preventing postoperative delirium in elderly surgical candidates requires proactive, multimodal perioperative strategies. Delirium represents an acute fluctuating change in attention, awareness, and baseline cognition. It predominantly affects frail older adults undergoing extensive surgical interventions. In addition to creating significant patient distress, postoperative delirium substantially increases the risk of institutionalization and thirty-day mortality. Clinicians recognize that intraoperative cerebral hypoperfusion and impaired oxygen delivery serve as potent triggers for neuroinflammatory cascades.

Therefore, optimizing intraoperative vasopressor therapy represents a modifiable target for delirium prevention. When anesthesiologists administer vasopressors that support both systemic vascular resistance and cardiac index, regional cerebral tissue oxygenation remains more stable. This physiological stability preserves blood-brain barrier integrity and suppresses catastrophic central nervous system inflammatory surges. Moreover, avoiding excessive fluctuations in mean arterial pressure prevents sudden reperfusion injury and microvascular shear stress. Implementing targeted depth of anesthesia monitoring alongside individualized hemodynamic goals further complements this protective strategy. Ultimately, refining vasopressor selection could transform standard anesthesia practice, offering a simple yet profoundly effective neuroprotective intervention for vulnerable geriatric populations.

Study Design of the Multicentre Randomized Trial

To resolve the debate between these two common agents, researchers designed a rigorous multicentre, double-blind, randomized controlled trial across seven major hospitals. The investigators plan to enroll 1,084 elderly participants scheduled for elective, major non-cardiac and non-neurosurgical procedures under general anesthesia. Researchers will randomize participants in an equal one-to-one ratio, stratified by study centre, to receive either a continuous intravenous infusion of phenylephrine or ephedrine. Clinicians will carefully titrate the designated infusion to maintain mean arterial pressure within twenty percent of pre-induction baseline values throughout the operative procedure.

The primary outcome focuses on the overall incidence of postoperative delirium within the first seven postoperative days. Furthermore, the trial incorporates several critical secondary endpoints to capture comprehensive recovery metrics. These secondary measures include delirium severity, validated pain scores at rest and during activity across seventy-two hours, and intensive care admission rates. Additionally, investigators will document total intensive care length of stay, overall postoperative hospitalization duration, in-hospital major adverse cardiovascular and cerebrovascular events, and thirty-day all-cause mortality. By enrolling a large cohort and employing strict blinding protocols, this trial aims to generate definitive, high-level evidence regarding vasopressor superiority.

Clinical Implications for Perioperative and Geriatric Practice

The results of this large-scale randomized trial carry immediate practical implications for anesthesiologists, surgeons, and geriatricians worldwide. In daily practice, clinicians frequently view phenylephrine and ephedrine as interchangeable tools for treating episodic hypotension under anesthesia. However, if ephedrine demonstrates a statistically significant reduction in postoperative delirium, clinical protocols must evolve away from routine pure alpha-agonist reliance. Anesthesiologists may shift toward hemodynamic strategies that prioritize cardiac output and cerebral microvascular perfusion over isolated arterial blood pressure numbers.

Furthermore, these findings could guide institutional formulary decisions and clinical pathway development. Standardizing vasopressor regimens according to age-specific neurovascular vulnerabilities would streamline intraoperative decision-making and reduce avoidable post-surgical complications. Such advancements are especially relevant for busy surgical centres managing high volumes of complex geriatric patients with multi-organ comorbidities. Additionally, the secondary cardiovascular endpoints will illuminate whether ephedrine introduces unacceptable arrhythmic risks compared to phenylephrine. Ultimately, integrating these trial insights will assist clinicians in personalizing vasopressor therapy, balancing cardiac performance against cerebrovascular protection to achieve superior postoperative recovery.

Frequently Asked Questions

Why is ephedrine hypothesized to protect against postoperative delirium better than phenylephrine?

Ephedrine provides both alpha- and beta-adrenergic stimulation, which maintains or increases forward cardiac output while raising blood pressure. In contrast, phenylephrine causes pure vasoconstriction and often triggers reflex bradycardia, reducing cardiac output. Because cerebral microvascular perfusion and regional cerebral oxygen saturation depend strongly on adequate cardiac output, ephedrine may sustain brain oxygenation more effectively during anesthesia. Consequently, this superior perfusion may prevent the neuroinflammatory cascades that trigger delirium.

How does intraoperative blood pressure target selection influence neurological outcomes?

Maintaining mean arterial pressure within twenty percent of baseline preserves organ perfusion and prevents cerebral hypoperfusion in vulnerable older adults. Significant blood pressure fluctuations disrupt cerebral autoregulation, starving fragile brain tissue of oxygen and glucose. Consequently, intraoperative hypotension strongly correlates with increased rates of postoperative cognitive dysfunction and delirium. Restoring pressure using physiologically tailored vasopressors protects the blood-brain barrier and mitigates cellular metabolic distress throughout prolonged operations.

What should clinicians monitor when choosing between these vasopressors in elderly patients?

Clinicians must evaluate baseline heart rate, myocardial contractility, and pre-existing cardiovascular comorbidities before selecting an intraoperative vasopressor. Phenylephrine remains suitable when tachycardia complicates hypotension, but it requires vigilance for severe bradycardia and low cardiac output. Conversely, ephedrine benefits patients with concurrent bradycardia, yet clinicians must monitor for tachyphylaxis and excessive tachyarrhythmias. Combining continuous arterial pressure monitoring with advanced hemodynamic and cerebral oxygenation assessments ensures balanced organ protection.

Disclaimer: This content is for informational and educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or clinical management. Never disregard professional medical advice or delay in seeking it because of something you have read in this article. Refer to the latest local and national guidelines for clinical practice.

References

1. Xu X et al. Effect of phenylephrine versus ephedrine on the incidence of postoperative delirium in elderly patients undergoing non-cardiac and non-neurosurgical procedures: protocol for a multicentre, double-blind, randomized, controlled trial. Ann Med. 2026 Dec undefined. doi: 10.1080/07853890.2026.2732555. PMID: 42745683.
2. Zheng C, Wang B, Fu J, Peng H, Chen Y, Hu X. Effect of phenylephrine versus ephedrine on the incidence of postoperative delirium in olderly adults undergoing knee arthroplasty under general anesthesia: a single-center trial. Sci Rep. 2024;14(1):17333.
3. Sessler DI, et al. Intraoperative Use of Phenylephrine versus Ephedrine and Postoperative Delirium: A Multicenter Retrospective Cohort Study. Anesthesiology. 2024;140(4):681-692.
4. Meng L. Cerebral Autoregulation and Vasopressor Therapy: Implications for Brain Protection during Surgery. Br J Anaesth. 2021;126(1):42-53.